Abbott Laboratories stock gets a boost from new infant formula and Libre Duo clearance
Published on 09/01/2026 at 09:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories Inc. (US0028241000) stock is trading a bit above $110 as of August 31, 2026, while investors weigh a fresh U.S. infant formula launch and recent FDA De Novo clearance for the Libre Duo 10-day glucose and ketone sensor alongside an upbeat analyst consensus on the shares. Per recent market data for the quarter ended June 30, 2026, Abbott has been cited with a Strong Buy rating and an average price target of $124.00, implying 11.1 percent upside from levels around $112.47 at the last close, which underlines the constructive view on the company.
New Similac whole-milk formula in the U.S.
A key near-term catalyst for Abbott Laboratories is the introduction of Similac 360 Total Care Made With Whole Milk, a new commercially sterile ready-to-feed liquid infant formula using whole milk for the U.S. market. A recent article on the Similac 360 Total Care Made With Whole Milk launch explains that Abbott is targeting parents who want the convenience and perceived nutritional benefits of whole milk in a formula that is ready to feed out of the bottle and manufactured under sterile conditions, which is particularly relevant after the sector's supply and safety challenges in recent years.
Per that coverage, the new formula is positioned as part of the broader Similac 360 Total Care family, extending Abbott's footprint in infant nutrition at a time when consumer confidence and brand differentiation matter greatly. The launch date of the whole-milk ready-to-feed product in the U.S. falls in late August 2026, making it a fresh development as of August 31, 2026, and adding another branded SKU that can support Abbott's nutrition segment revenue trajectory in the second half of 2026 and into 2027 if adoption is strong.
Libre Duo 10-day FDA De Novo clearance expands diabetes technology
Beyond infant formula, Abbott Laboratories is also building momentum in diabetes technology through the Libre Duo 10-day sensor platform. A recent overview of Libre Duo 10-day developments notes that Abbott won FDA De Novo clearance for Libre Duo 10 Day, a wearable glucose and ketone sensor approved for users aged two years and older, offering real-time trend information and alerts for rising ketone levels. The same source indicates that the U.S. launch is slated for late 2026, which means the product will fall squarely within the current planning horizon for Abbott's diabetes-care segment.
The De Novo clearance pathway is often used for novel devices where no predicate exists, and securing such clearance for Libre Duo 10 Day positions Abbott to expand beyond pure glucose monitoring into broader metabolic status tracking. The sensor's ability to monitor both glucose and ketones in a single wearable could widen its appeal to people with type 1 diabetes, those at risk of diabetic ketoacidosis, and potentially certain fitness-oriented users formally or informally advised by clinicians. With an expected late 2026 U.S. launch, Libre Duo 10 Day could contribute incremental revenue to Abbott's diabetes-care business in 2027 and beyond, particularly if payers and clinicians endorse the added ketone-monitoring functionality.
In the same recap, an analyst price target on Abbott Laboratories has been lifted to $135 from $115, indicating that at least one research house now expects the shares to appreciate by a double-digit percentage from current levels around $112 and aligning with a more optimistic view of the company's pipeline, including Libre Duo 10 Day. This increase in the price target is consistent with the reported Strong Buy consensus and average target of $124.00, which collectively point to visible upside keyed to Abbott's combination of diagnostics, medical devices, nutrition, and established cardiovascular and neuromodulation offerings.
Analyst consensus and valuation context
Recent coverage of Abbott Laboratories equity research notes that the stock carries a Strong Buy consensus rating among covering analysts, with an average price target of $124.00 compared to a last closing level of $112.47 as of late August 2026. An analyst-opinion summary on Abbott and other healthcare names highlights that this target implies 11.1 percent potential upside, which provides a concrete quantitative benchmark for investors comparing Abbott to other diversified healthcare companies.
In that same context, the report mentions that Abbott Laboratories shares closed the recent session at $112.47, which is modestly higher than the $110.10 price cited in a separate dividend-focused article that looked at healthcare stocks capable of raising distributions through multiple downturns. A dividend-growth discussion covering Abbott Laboratories states that Abbott trades at $110.10 and that the shares have seen an 8.57 percent pullback year to date, lifting the dividend yield to 2.22 percent as of August 31, 2026. The same article points out that Abbott's quarterly payout has increased from $0.59 to $0.63 per share this year, giving an annualized forward dividend of $2.52 per share, which is a tangible sign of management's confidence in cash flow.
The combination of an 8.57 percent year-to-date share-price decline and a 2.22 percent dividend yield places Abbott in a category of healthcare stocks that have lagged the broader market but offer visible shareholder returns through a growing payout. For income-oriented investors, a forward dividend of $2.52 on a price point near $110 equates to the cited yield, while for total-return investors, the gap between current price and the $124 average target and the $135 raised target provides a quantified lens on potential medium-term appreciation if Abbott executes effectively on its growth initiatives.
From a valuation standpoint, the share-price level around $110 to $112 as of August 31, 2026 means Abbott is trading below the loftier targets but still at a premium to some more narrowly focused device makers, reflecting the company's diversified portfolio across diagnostics, devices, nutrition, and branded pharmaceuticals. The two dividend increases within economic downturns referenced in the dividend article underscore that Abbott has historically been willing to lift its payout even when macro conditions are challenging, which can be a supportive factor for valuation multiples in defensive sectors like healthcare.
Recent trading and market data snapshot
On the market-data side, a portfolio-activity report for the quarter ended June 30, 2026 cited Abbott Laboratories at a last price of $110.75 with a daily change of 0.35 percent, underscoring that the shares have been trading in a relatively tight range around the $110 mark in recent sessions. A Q2 2026 portfolio-activity overview including Abbott stock data lists Abbott among the holdings with that price, which aligns broadly with the $110.10 dividend-article figure and the $112.47 close in the analyst summary.
While the precise intraday quote as of September 1, 2026 is subject to market fluctuations, the cluster of reported prices between $110.10 and $112.47 at the end of August 2026 suggests that Abbott stock has been consolidating just above the $110 level. This band can serve as a reference zone for investors watching whether the shares break higher toward the $124 and $135 targets, or instead retest lower support levels if sentiment toward healthcare or Abbott-specific pipelines softens.
From a performance perspective, the 8.57 percent year-to-date pullback referenced in the dividend-focused coverage offers a concrete comparison versus the broader U.S. equity market, where many large-cap indices have been positive in 2026. That decline, coupled with the increased dividend, means that a portion of shareholder return is now coming in cash rather than price appreciation, and it also means that Abbott's valuation on metrics such as price-to-earnings and enterprise-value-to-EBITDA may be less stretched than at prior peaks, even though exact multiples were not detailed in the publicly available snippets.
Dividend growth and income profile
The dividend-growth story is central to Abbott Laboratories' current equity narrative. The referenced article on healthcare dividend raisers notes that Abbott has continued to lift its payout across multiple economic downturns, including two recessions, underscoring the resilience of its cash-generation capacity. The latest move from a $0.59 quarterly dividend to $0.63 per share in 2026 represents a 6.8 percent increase in the per-share payment, which compounds over time for long-term investors who reinvest dividends.
With an annualized forward dividend of $2.52 per share on a stock price around $110.10 as of August 31, 2026, the yield of 2.22 percent compares favorably to many other large-cap healthcare names that either offer similar yields with slower growth or lower yields with faster capital gains. For investors constructing an income portfolio, the combination of yield and growth rate is a key consideration, and Abbott's track record of raising its dividend through challenging periods is a tangible competitive strength.
Dividend policy also interacts with capital allocation decisions across Abbott's business lines. Funding research and development for products like Libre Duo 10 Day and investing in manufacturing capacity for Similac 360 Total Care Made With Whole Milk are capital-intensive, but Abbott has managed to support these initiatives while maintaining and increasing the dividend. This balance indicates a disciplined approach to growth and shareholder returns, although investors always need to watch whether future payout increases remain supported by underlying earnings and free cash flow.
Earnings and fundamental picture
While the day-filtered search results do not provide a full breakdown of Abbott Laboratories' latest quarterly income statement, the available evidence makes it clear that the company's most recent reporting period is at least the second quarter of 2026, ending June 30, 2026. The portfolio-activity document referencing Abbott at a price of $110.75 in the context of Q2 2026 holdings confirms that the company has reported or otherwise guided for that period, and the analyst-consensus data implicitly incorporates those fundamentals in setting the $124 average target and Strong Buy rating.
Historically, prior fiscal years such as 2023 and earlier featured revenue growth and margin development that supported Abbott's dividend increases, but those figures fall outside the strict freshness window for September 1, 2026 and thus serve primarily as background rather than as current metrics. What matters most for investors today are Abbott's 2026 revenue trends, earnings per share, and segment performance in areas like diabetes-care, diagnostics, cardiovascular devices, neuromodulation, and nutrition, as reflected in the current consensus view.
With the available information, one can infer that analyst models incorporate rising contributions from new products such as Libre Duo 10 Day and Similac 360 Total Care Made With Whole Milk, while also accounting for the incremental dividend cost and the modest share-price pullback year to date. The uplift from $115 to $135 in one documented price target suggests that analysts are recalibrating their forecasts upward based on pipeline visibility and perhaps better-than-expected execution or demand in key franchises, even though specific revenue and EPS numbers for Q2 2026 are not detailed in the snippets.
In this framework, Abbott's fundamentals can be thought of as a blend of steady cash flows from established products and potential upside from new launches. The company's ability to maintain a Strong Buy consensus and an 11.1 percent implied upside from the $124 average target despite the year-to-date decline indicates that analysts see the pullback as an opportunity rather than a structural warning sign. For investors, the key question is whether the forthcoming quarters confirm these expectations through reported revenue growth, margin resilience, and earnings delivery.
Product spotlight: Similac 360 Total Care Made With Whole Milk
Among Abbott Laboratories' many products, Similac 360 Total Care Made With Whole Milk stands out as a representative offering in the nutrition segment in 2026. The ready-to-feed liquid formula uses whole milk and is manufactured under sterile conditions, aiming to provide parents with a convenient and trusted option at a time when infant nutrition remains a sensitive topic. A report on Abbott targeting parents with the new whole milk formula explains that Abbott will begin selling this new ready-to-feed Similac variant on a late August 2026 launch timeline, making it the first time whole milk has been used in sterile liquid infant formula in the U.S.
This product is particularly significant because it addresses a segment of parents described as wary or cautious following prior industry issues in infant formula supply and safety. By offering a sterile liquid formula that incorporates whole milk, Abbott is attempting to differentiate itself on both convenience and perceived nutritional quality, while also leveraging the strong brand recognition of Similac. The innovation lies in the combination of whole-milk formulation with sterile ready-to-feed packaging, which reduces preparation steps and potential contamination compared to powdered formulas mixed at home.
From a business perspective, Similac 360 Total Care Made With Whole Milk adds to Abbott's broader portfolio of infant and pediatric nutrition products and could support margin improvement if priced at a premium to traditional powdered formula or standard ready-to-feed options. The product's performance will depend on how quickly retailers and healthcare providers adopt it, whether parents are willing to pay for the added perceived benefits, and how competitors respond with their own innovations or marketing campaigns. For investors, tracking early sales trends and any commentary from management in upcoming earnings calls will be crucial to gauging how much incremental revenue and profit this product can deliver.
Shares trade just above $110 as investors watch pipelines
Against this backdrop of new product launches and a supportive analyst stance, Abbott Laboratories stock has been trading slightly above $110 in late August 2026, with reported prices ranging from $110.10 to $112.47 and a daily gain of 0.35 percent cited at $110.75 in one Q2 2026 portfolio-activity snapshot. As of the most recent completed U.S. trading session on August 31, 2026, the dividend-focused coverage referenced a price of $110.10 and a year-to-date pullback of 8.57 percent, which together suggest a stock that has corrected but remains well within its multi-year range.
Looking ahead from September 1, 2026, investors will be watching Abbott's next set of quarterly results and any formal guidance updates to see whether the combination of Similac 360 Total Care Made With Whole Milk, Libre Duo 10 Day, and other pipeline elements translates into the revenue and earnings growth embedded in consensus models. The quantified gap between the current price zone and the $124 average and $135 raised price targets provides a numerical framework for potential upside, while the 2.22 percent dividend yield offers a visible income component for those willing to hold the shares through any short-term volatility.
